High expression of EGOT was associated with favorable OS and RFS) in breast cancer patients, while loss of ITPR1 indicated worse RFS in the HMUCC cohort (Fig. 6a and b; Additional file 2: Figure S7a). Here, EGOT is linked to breast carcinoma.